not crypto- Top Reviews

Ali launched the e-commerce app "Tao" in Japan: in the future, it will expand its staff to explore the local market. On December 12, Alibaba Group held a briefing on the e-commerce app "Tao" launched for the Japanese market. The company said that it will expand its staff in the future and fully explore the Japanese market. According to reports, the APP was launched in October, selling more than 3 million kinds of goods such as clothing, groceries and digital related products. It also has the function of recommending goods by artificial intelligence (AI) according to consumers' preferences. The goods are mainly delivered from China after the consumer places an order, and arrive in Japan a few days later. (Interface News)Comments on Hong Kong stocks: Hang Seng Index fell by 2.09%, Hang Seng Technology Index fell by 2.63%, Hong Kong stocks closed, Hang Seng Index fell by 2.09% and Hang Seng Technology Index fell by 2.63%. Domestic insurance stocks and domestic housing stocks were among the top losers, with Sunac China falling more than 8%, and Xpeng Motors, China Pacific Insurance and Zijin Mining falling more than 5%.Astana Airlines resumed the route from Urumqi to Astana. On December 13th, according to Astana Airlines, Astana Airlines resumed the Urumqi-Astana flight from December 1st, with 2 flights per week. The resumed KC flight KC287 departs from Astana (NQZ) at 19: 30 every Tuesday and Saturday and arrives in Urumqi (URC) at 1: 00 the next day; KC288 departs from Urumchi (URC) at 2 o'clock every Wednesday and Sunday and arrives in Astana (NQZ) at 1: 45, all of which are local time. In addition, Astana Airlines also operates regular flights from Urumqi to Almaty, four times a week.

On the 13th, the European futures of the container freight index rose by 7.03%, and the latest main contract positions changed as follows. According to the data of the exchange, as of December 13th, the European futures of the main contract container freight index closed at 2502, up or down by +7.03%, with a turnover of 41,900 lots. The position data showed that the top 20 seats were net, and the difference position was 3,022 lots. A total of 78,900 lots of European futures contracts were traded, an increase of 8,599 lots over the previous day. The first 20 seats in the contract held 25,100 lots, an increase of 466 lots over the previous day. The short positions in the top 20 seats of the contract were 22,100 lots, a decrease of 120 lots from the previous day. (Sina Futures)Qinchuan Machine Tool: The company's machine tool business section can provide a variety of processing equipment for humanoid robot manufacturers. Qinchuan Machine Tool said on the interactive platform that the company's machine tool business section can provide a variety of processing equipment for humanoid robot manufacturers, such as gear grinder, planetary roller screw pair key processing equipment thread grinder, etc. The spare parts business section of the company has the foundation of R&D and manufacturing of planetary roller screw by-products. Now, it has gradually started small batch production and verified its application. In the future, according to the market demand, it will gradually improve the detection and processing means and build its capacity.Xia Yiping, CEO of Extreme Vietnam: I won't run away! Agreeing with employees' reasonable demands, communication with Baidu and Geely working groups has been established. The reporter learned from the inside of Extreme Yue Automobile that on the evening of December 12, Xia Yiping, CEO of Extreme Yue Automobile, informed all employees of the latest progress by means of synchronous news of flying books. Xia Yiping said: "Shanghai, the social security provident fund tax payment is completed; Beijing Jidu Technology has paid the provident fund before, because the system can't pay the social security tax tonight (December 12), and will go to the counter to pay it early tomorrow (December 13); Beijing jidu service, social security provident fund tax payment is completed; Wuhan, the social security provident fund tax payment is completed; Zhejiang, the provident fund has been paid before, and the social security tax will be paid tomorrow (December 13); In the remaining cities, the social security provident fund has been paid, and the individual tax will be paid tomorrow (December 13). " (national business daily)

Ha Sanlian: Four kinds of drugs are planned to win the bid for national centralized procurement. Ha Sanlian announced that the company and its wholly-owned subsidiary Lanxi Pharmaceutical participated in the tenth batch of national centralized procurement of drugs organized by the state. The company's esmolol hydrochloride injection, pentoxifylline injection, potassium chloride injection, and tandospirone citrate tablets of Lanxi Pharmaceutical intend to win the bid for this centralized procurement. If the subsequent purchase contract is signed and implemented, it will help to expand the sales of related products and improve the market share and brand influence. The prices of the above-mentioned drugs are respectively 1.34 yuan for esmolol hydrochloride injection, 0.59 yuan for pentoxifylline injection, 0.16 yuan for potassium chloride injection and 6.56 yuan for tandospirone citrate tablets.Jimi Technology: The wholly-owned subsidiary has received the designated notice of development from a well-known domestic automobile main engine factory, and Jimi Technology announced that Yibin Jimi, a wholly-owned subsidiary, has received the designated notice of development from a well-known domestic automobile main engine factory, and will become the designated development supplier of the customer's car projector to supply intelligent cockpit display products.Hengrui Pharma: SHR-2173 injection was approved for clinical trial. Hengrui Pharma announced that its subsidiary, Guangdong Hengrui Pharma Co., Ltd., received the Notice of Approval for Clinical Trial of SHR-2173 injection approved and issued by National Medical Products Administration, and agreed to carry out clinical trial. The indication is lupus nephritis. SHR-2173 injection is a therapeutic biological product independently developed by the company, and the research and development expenses have been invested about 45.03 million yuan. The period from research and development to listing of drugs is long, there are many links, and there are uncertain factors. The company will actively promote research and development projects and fulfill its information disclosure obligations.